What is the core technology behind IntelGenx?

IntelGenx focuses on two primary proprietary technologies: VersaFilm and VersaTab. VersaFilm is an oral thin film delivery system designed for rapid disintegration, improved absorption, and easier compliance for patients who struggle to swallow pills. VersaTab is a multilayer tablet technology. These technologies are used to reformulate existing, approved drugs to improve their delivery and efficacy.

How does the company mitigate regulatory risk?

The company’s motto, 'We Make Approved Drugs Better,' indicates a 505(b)(2) regulatory pathway strategy. By using drugs that are already FDA-approved and simply changing the delivery method, they bypass the high-risk, high-cost early-stage drug discovery phase, focusing instead on bioequivalence and improved patient outcomes.

What are the primary market opportunities identified in the deck?

IntelGenx identifies several multi-billion dollar opportunities. The largest targeted segments within their VersaFilm platform include Schizophrenia (Loxapine) at $5.2B, Erectile Dysfunction (Cialis/Tadalafil) at $4.2B, Migraine (Rizatriptan) at $2B, and Opioid Dependence (Suboxone) at $1.7B.

Does IntelGenx manufacture its own products?

Yes, the deck emphasizes an in-house manufacturing approach. Slide 10 details their full capabilities, including blending, coating, and packaging. This 'one-stop shopping' model for clients is designed to reduce dependence on external partners, protect intellectual property, and increase overall profitability.

What is the financial status of the company as of the 2016 presentation?

The company reported record results in Q3 2015, achieving $2.38M in revenue for the quarter and $3.59M for the first nine months of the year. This represented a substantial increase from 2014 figures. The deck also notes that the company achieved profitability during this period.

IntelGenx Corp. Pitch Deck (2016): 17-Slide Breakdown

See all 17 slides of the IntelGenx Corp. pitch deck — a 2016 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

IntelGenx Corp. (IGX) is a drug delivery company specializing in oral thin films (VersaFilm) and tablets (VersaTab). Their 2016 investor presentation highlights a strategy of making 'approved drugs better' to reduce regulatory risk and accelerate time to market. With a total addressable market of $19B, the company leverages the expertise of its CEO, a co-developer of Listerine breath strips, to innovate in pharmaceutical delivery. The deck showcases a robust pipeline of products across various stages of clinical development and filing, supported by in-house manufacturing capabilities. While t…

Key takeaways

The company targets a total addressable market (TAM) of $19B through proprietary oral drug delivery technologies (Slide 4).
IntelGenx CEO Horst G. Zerbe is credited as the co-developer of Listerine breath strips, providing significant domain authority (Slide 2).
The VersaFilm technology alone addresses a $17B market, including targeted sales for Opioid Dependence ($1.7B) and Schizophrenia ($5.2B) (Slide 6).
Revenue showed significant year-over-year growth, rising from $0.45M in Q3 2014 to $2.38M in Q3 2015 (Slide 12).
The product pipeline includes 13 distinct indications, with Forfivo XL already launched and others in various stages from formulation to filing (Slide 8).
IntelGenx utilizes an in-house manufacturing approach covering blending, coating, and packaging to increase profitability and protect IP (Slide 10).
The leadership team boasts over 100 years of combined industry experience and currently employs 20 people, including 8 Ph.D.s (Slide 14).
The company is publicly traded on the TSX-V (IGX) and OTCQX (IGXT), as noted on the title slide (Slide 1).

IntelGenx Corp. Investor Presentation Analysis

IntelGenx Corp. (IGX) provides a masterclass in how a specialty pharmaceutical company can position itself as a high-growth, lower-risk investment. By focusing on drug delivery rather than drug discovery, the company leverages existing clinical data to bring 'improved' versions of blockbuster drugs to market. This teardown examines their February 2016 presentation, which served as a progress report for a company already listed on the TSX-V and OTCQX.

Slide 1: Title and Positioning

The cover slide establishes the company's core value proposition: 'Innovative Drug Delivery Solutions' with the subtitle 'We Make Approved Drugs Better.' This is a critical distinction in the biotech world. It signals to investors that the company is not gambling on unproven molecules, but rather optimizing known quantities. The slide also lists their ticker symbols (TSX-V: IGX and OTCQX: IGXT), immediately identifying them as a publicly traded entity rather than a private startup.

Slide 2: The Listerine Connection

Slide 2 uses a highly recognizable consumer product—Listerine PocketPaks—to validate their technology. By stating that the IGX CEO was a co-developer of the Listerine breath strips, the company bridges the gap between a familiar consumer item and a complex medical application. The slide lists the benefits of oral thin films: ideal for elderly and pediatric patients, and offering quicker action to relieve symptoms. This slide effectively answers the 'Why now?' and 'Why this technology?' questions by pointing to a proven, successful delivery format.

Slide 4: Investment Highlights and TAM

This slide introduces the scale of the opportunity. It cites a $19B Total Addressable Market (TAM) for their proprietary technologies. Specifically, it breaks down the TAM into $17B for VersaFilm and $1.7B for VersaTab. Key achievements mentioned include market momentum with Forfivo XL tablets, European marketing approval for RIZAPORT for migraines, and record Q3 revenue and profitability. This slide serves as an executive summary, hitting the high notes of technology, market size, and financial performance.

Slide 6: VersaFilm Deep Dive

Slide 6 focuses exclusively on the VersaFilm platform. It reiterates the $17B market opportunity and lists specific targeted sales figures for four major indications: Opioid Dependence ($1.7B), Migraine ($2B), Schizophrenia ($5.2B), and Erectile Dysfunction ($4.2B). The slide also mentions that they have two film products awaiting FDA approval and successful pivotal bioequivalence studies, which are major de-risking milestones for pharmaceutical investors.

Slide 8: The Product Pipeline

The pipeline slide is perhaps the most important in any pharmaceutical deck. IntelGenx shows a diversified portfolio of 13 indications. The chart tracks progress from 'Formulation Development' through to 'Launch.' Notably, Forfivo XL is shown as fully launched. The slide also lists 'Partnering Availability,' showing that while some products are partnered with firms like Par Pharmaceuticals and Edgemont Pharmaceuticals, many remain 'Available,' representing future licensing revenue opportunities for the company.

Slide 10: In-House Manufacturing

IntelGenx highlights its vertical integration here. By establishing full manufacturing capabilities—blending, coating, and packaging—the company positions itself as a 'one-stop shop' for clients. The stated goals are to increase profitability, reduce dependence on external partners, and protect intellectual property. For an investor, this suggests better margin control and a more defensible business model than a company that purely outsources production.

Slide 12: Financial Execution

This slide provides the 'proof in the pudding' regarding their commercial strategy. A bar chart compares Q3 2015 revenue ($2.38M) to Q3 2014 ($0.45M), showing a massive jump. Similarly, the nine-month totals rose from $0.83M to $3.59M. The headline 'Record Results in Q3 Demonstrates Strong Execution of Strategy' reinforces the narrative that the company is successfully transitioning from R&D to a revenue-generating commercial entity.

Slide 14: Leadership and Expertise

The team slide emphasizes 'Visionary, Experience Leadership' with over 100 years of combined industry experience. It features six key executives, highlighting their backgrounds at major firms like LTS, RBC, and Paladin. The mention of 'Currently 20 Employees, 8 Ph.D.s' provides a sense of the company's lean but highly specialized workforce. The CEO, Horst G. Zerbe, is again highlighted for his 30+ years of experience and 40+ patents.

Slide 16: Conclusion

The deck concludes with a simple 'Thank You' and the company website. As a public company presentation, it lacks the 'Ask' slide typical of a private venture round, but the preceding slides serve as a cumulative argument for why the stock is a compelling buy based on pipeline maturity and revenue growth.

What IntelGenx Does Well

The deck is exceptionally clear about its business model. By focusing on the 505(b)(2) regulatory pathway—improving existing drugs—they present a lower-risk profile than traditional biotech. The use of the Listerine analogy is a brilliant way to make a technical pharmaceutical delivery system instantly understandable to a generalist investor. Furthermore, the pipeline slide (Slide 8) is comprehensive, showing both the breadth of their applications and the specific stage of each project, which is the primary metric for valuing such companies.

What is Missing from the Deck

Because this is a 2016 investor presentation for a public company, it omits several elements required in a startup pitch. There is no 'Problem' slide in the traditional sense; it assumes the audience understands that swallowing pills is a challenge for some patients. There is also no detailed breakdown of unit economics or a specific 'Use of Funds' slide. While they mention 'profitability' on Slide 4, they do not provide a full P&L or cash flow statement, which would be necessary to understand their burn rate and runway.

Founder Takeaways: What to Copy

The 'Analogous Success' Strategy: If your technology is complex, find a consumer-facing equivalent (like the Listerine strips) to explain it quickly. · De-risking Through Regulation: Highlighting that you are working with 'Approved Drugs' immediately lowers the perceived risk of clinical failure. · Visual Pipeline Tracking: The horizontal bar chart on Slide 8 is the industry standard for a reason; it clearly communicates progress and future catalysts. · Vertical Integration as a Moat: Showing that you own the manufacturing process (Slide 10) signals to investors that you have better control over your IP and margins than a 'virtual' company. · Quantifying the TAM by Segment: Instead of just giving one big number, IntelGenx breaks their $19B TAM down into specific, actionable market segments (Slide 6).

Frequently asked questions

What is the core technology behind IntelGenx?: IntelGenx focuses on two primary proprietary technologies: VersaFilm and VersaTab. VersaFilm is an oral thin film delivery system designed for rapid disintegration, improved absorption, and easier compliance for patients who struggle to swallow pills. VersaTab is a multilayer tablet technology. These technologies are used to reformulate existing, approved drugs to improve their delivery and efficacy.
How does the company mitigate regulatory risk?: The company’s motto, 'We Make Approved Drugs Better,' indicates a 505(b)(2) regulatory pathway strategy. By using drugs that are already FDA-approved and simply changing the delivery method, they bypass the high-risk, high-cost early-stage drug discovery phase, focusing instead on bioequivalence and improved patient outcomes.
What are the primary market opportunities identified in the deck?: IntelGenx identifies several multi-billion dollar opportunities. The largest targeted segments within their VersaFilm platform include Schizophrenia (Loxapine) at $5.2B, Erectile Dysfunction (Cialis/Tadalafil) at $4.2B, Migraine (Rizatriptan) at $2B, and Opioid Dependence (Suboxone) at $1.7B.
Does IntelGenx manufacture its own products?: Yes, the deck emphasizes an in-house manufacturing approach. Slide 10 details their full capabilities, including blending, coating, and packaging. This 'one-stop shopping' model for clients is designed to reduce dependence on external partners, protect intellectual property, and increase overall profitability.
What is the financial status of the company as of the 2016 presentation?: The company reported record results in Q3 2015, achieving $2.38M in revenue for the quarter and $3.59M for the first nine months of the year. This represented a substantial increase from 2014 figures. The deck also notes that the company achieved profitability during this period.

Cover slide of the IntelGenx Corp. pitch deck — 2016 — IntelGenx Corp. pitch deck, slide 1 (2016)

IntelGenx Corp. pitch deck: the facts

Company: IntelGenx Corp.
Year: 2016
Stage: Public (TSX-V: IGX, OTCQX: IGXT)
Slides: 17
Sector: Pharmaceuticals / Drug Delivery
Deck type: Investor Presentation
Outcome: Publicly Traded
Headquarters: Saint-Laurent, Quebec, Canada

IntelGenx Corp. pitch deck PDF

The full IntelGenx Corp. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the IntelGenx Corp. pitch deck was used for

This is IntelGenx’s **February 18, 2016 investor presentation** for public-market investors, given as a TSX Venture/OTCQX-listed company focused on innovative oral drug delivery platforms, notably oral thin films branded VersaFilm™. The deck highlights commercialization of thin-film formulations of approved drugs (e.g., Rizaport™ for migraine, Suboxone targeting opioid dependence, tadalafil for erectile dysfunction, antipsychotics for schizophrenia) and the company’s first European marketing approval of Rizaport™. It also emphasizes record Q3 2015 revenue, the Forfivo XL® tablet product, and a strategy to expand into additional high-value indications via in-house manufacturing capabilities. Although the deck does not specify a discrete private round, in 2016–2017 IntelGenx undertook capital-raising transactions as a public issuer, including the August 2016 sale of its Forfivo XL® royalty for $6 million and, later, a 2017 convertible debenture offering primarily for capital expansion and clinical studies.

Business model: IntelGenx is a specialty pharmaceutical company that develops and manufactures innovative oral drug delivery systems, primarily **oral thin films (VersaFilm™)** and specialized tablet technologies (VersaTab™, AdVersa™), to improve the performance and patient acceptability of mostly already-approved drugs.

Year: 2017
Headquarters: Saint-Laurent, Quebec, Canada.
Industry: Pharmaceuticals / Drug Delivery.

Round: Convertible debenture offering by a public company (IntelGenx Technologies Corp.).

Raised: CDN$6,838,000 of convertible unsecured subordinated debentures (a public prospectus offering completed July 12, 2017).

Use of funds as presented: IntelGenx stated that the aggregate net proceeds from the debenture offering would be used for capital expansion, clinical studies, product development, and general working capital requirements.

What happened after the IntelGenx Corp. deck

Following the February 18, 2016 investor presentation, IntelGenx reached several key milestones tied to the themes of the deck: regulatory and IP validation of its Rizaport™ thin-film migraine product, monetization of Forfivo XL® royalties to fund its film pipeline, and a convertible debenture financing to support capital expansion and clinical development programs. The company continues to operat

Obtained its **first European marketing approval of Rizaport™** (rizatriptan oral thin film) for migraine before or arou
On August 5, 2016, **sold its U.S. royalty on future Forfivo XL® sales to SWK Holdings Corporation for $6 million (appro
On July 12, 2017, **completed a CDN$6.838 million convertible unsecured subordinated debenture offering**, with 8% inter
Announced patent grants and notices of allowance protecting the **VersaFilm™ formulation used in Rizaport™**, including

What the IntelGenx Corp. deck got right

Clear platform narrative tied to multiple large indications. The deck showcases a **coherent platform strategy** built around VersaFilm™ oral thin films, explicitly linking the technology to high-value indications such as opioid dependence (Suboxone), migraine (Rizaport™), erectile dysfunction (tadalafil/Cialis®), and schizophrenia (antipsychotic films), which helps investors understand how a single delivery technology can be leveraged across multiple therapeutic areas.
Regulatory and IP validation for the lead thin-film product. IntelGenx highlights having achieved its **first European marketing approval for Rizaport™** and later patent grants protecting its VersaFilm™ formulation, providing concrete regulatory and IP milestones that support the claim of a de-risked, commercially relevant thin-film technology rather than just a preclinical concept.
Existing commercial product and demonstrated revenue traction. The deck emphasizes prior commercial success with **Forfivo XL® extended-release tablets** and presents record Q3 2015 revenue and profitability, demonstrating that IntelGenx already has revenue-generating products and operational execution, which strengthens investor confidence in its ability to bring new formulations to market.
Vertically integrated manufacturing strategy for thin films. Slides on **in-house manufacturing** detail IntelGenx’s strategy to control blending, coating, and packaging, integrate pharmaceutical services with IP protection, and offer “one-stop shopping” to partners, suggesting a vertically integrated model that could improve margins and reduce reliance on contract manufacturers.
Strong patient-centric value proposition for oral films. By focusing on **patient-friendly oral films** that disintegrate rapidly without water and are ideal for elderly, children, and patients with dysphagia or psychiatric conditions, the deck articulates a clear clinical and patient-acceptance rationale for reformulating existing drugs rather than competing purely on price.
Targeting large, multi-indication market opportunities. The deck ties the company’s oral thin film pipeline to **large quantified markets**, including a stated $17B TAM for VersaFilm™ applications and $19B overall TAM for its proprietary oral drug delivery technologies, conveying the scale of potential upside if multiple programs reach commercial adoption.

What could have been stronger

High-level TAM figures lack transparent breakdown or sourcing. The deck references a **$19B total addressable market (TAM)** and a $17B TAM for VersaFilm™ without clearly breaking down how these figures are derived by indication, geography, or time horizon, making it difficult for investors to verify the realism of the opportunity sizing directly from the slides.
Limited forward-looking financial visibility and capital plan in the deck. While the deck mentions record Q3 revenue and profitability, only limited historical financial detail (e.g., one chart of Q3 and nine-month revenue) is provided, with **no forward-looking revenue projections, unit economics, or capital needs** tied explicitly to pipeline milestones.
Pipeline status and partnering details are not fully specified. The pipeline slide highlights multiple target indications (opioid dependence, migraine, erectile dysfunction, schizophrenia) but does not clearly map each program to its **regulatory status, development stage, or partner structure**, leaving ambiguity about which assets are partnered, self-commercialized, or still preclinical at the time.
Manufacturing capabilities described qualitatively without capacity or quality metrics. The manufacturing slide touts in-house blending, coating, and packaging but does not quantify **installed capacity, quality certifications (e.g., cGMP status), or capex requirements**, limiting an investor’s ability to assess execution risk and scalability from the deck alone.

How an investor would read this deck

What draws attention

Validation of IntelGenx’s thin-film technology via **first European marketing approval of Rizaport™** for migraine and patent protection for the VersaFilm™ formulation, which indicates regulatory and IP progress rather than just a concept-stage platform.
The August 2016 sale of the Forfivo XL® royalty to **SWK Holdings Corporation for $6 million (CAD$8 million)**, described by IntelGenx as the largest influx of capital in company history, and its stated intention to deploy proceeds into advancing the VersaFilm™ oral film pipeline.
IntelGenx’s **2017 convertible debenture offering of CDN$6.838 million**, including terms (8% unsecured subordinated debentures maturing June 30, 2020) and stated use of proceeds for capital expansion, clinical studies, product development, and working capital, which contextualizes the company’s fun
The oral thin film platform’s focus on **patient populations with difficulty swallowing tablets (elderly, pediatrics, psychiatric patients)** and high-value therapeutic areas (migraine, opioid dependence, erectile dysfunction, schizophrenia), which aligns with clear unmet needs and potentially stron
IntelGenx’s shift toward **in-house manufacturing** to integrate pharmaceutical services and IP protection and reduce reliance on external partners, which could improve gross margins and control over product quality and timelines if executed successfully.

Risks that stand out

IntelGenx’s business is highly dependent on **successful regulatory approvals and commercialization** of reformulated versions of existing drugs (e.g., rizatriptan films, tadalafil films, Suboxone films), so delays or failures in clinical development, bioequivalence studies, or regulatory review cou
Given the company’s focus on repurposing **branded molecules owned by third parties**, IntelGenx faces **partner and licensing risk**, including potential changes in partner strategy, renegotiation of royalty terms, and dependence on counterparties such as Edgemont Pharmaceuticals and SWK Holdings f
The company operates in therapeutic areas with **intense generic and branded competition** (migraine, erectile dysfunction, opioid dependence, schizophrenia), so even improved delivery formats may face pricing pressure and challenges in gaining formulary access and market share.
IntelGenx has historically relied on capital-raising transactions such as the **Forfivo royalty sale and convertible debentures**, indicating ongoing **financing risk** and the need for continued access to equity or debt markets to fund capital expansion, clinical programs, and working capital.
Execution risk around **scaling in-house manufacturing** and maintaining quality standards is significant; any deficiencies in manufacturing capacity, cGMP compliance, or supply reliability could impede launches and damage relationships with partners and regulators.

Questions this deck invites

What is the current and historical revenue mix between **legacy tablet products like Forfivo XL®** and newer thin-film products such as Rizaport™ and other VersaFilm™-based formulations, and how did the 2016 royalty sale to SWK affect futur
For each major VersaFilm™ program (Rizaport™, Suboxone film, tadalafil film, antipsychotic film), what were the **exact development stages and regulatory statuses** at the time of the 2016 deck, and how have those evolved since then (approv
Which products are **partnered versus self-commercialized**, what are the economic terms of key agreements (royalty rates, milestones, co-promotion rights), and how dependent is IntelGenx on any single commercial partner or product line for
What are the **capabilities and certifications** of IntelGenx’s in-house manufacturing facility (e.g., cGMP compliance, capacity, scalability), and what capital expenditures from the 2016–2017 financings were required to bring or keep that
How does IntelGenx’s **competitive positioning** in oral thin film drug delivery compare to other film and fast-dissolve technology players in terms of IP coverage, bioequivalence performance, cost of goods, and breadth of partnered product

What founders can take from the IntelGenx Corp. deck

A public-company investor deck can effectively highlight a **platform story** by linking a single core technology (VersaFilm™ oral thin films) to multiple large therapeutic markets (migraine, opioid dependence, erectile dysfunction, schizophrenia) while still grounding the narrative in specific name
Including **regulatory and IP milestones**—such as first European marketing approval for Rizaport™ and granted patents protecting the film formulation—adds credibility and shows that a drug delivery platform has moved beyond concept into de-risked, late-stage assets.
Connecting operational initiatives like building **in-house manufacturing capabilities** to the financial story (margin expansion, reduced dependence on external partners) helps investors see how infrastructure investment supports both strategic control and long-term profitability.
Demonstrating **historical financial traction** (e.g., record Q3 revenue and profitability) alongside pipeline opportunities reassures public-market investors that the company is not purely pre-revenue, even when future growth depends on new formulations and indications.
Disclosing large **TAM figures** without detailed bottom-up breakdown can weaken investor confidence; more granular segmentation by indication, geography, and time frame would make the opportunity sizing more persuasive and easier to diligence.
Showing how non-dilutive or structured transactions (like selling a royalty stream) fit into a **capital allocation strategy** for advancing a core pipeline can be compelling, but investors will still require clarity on the long-term trade-offs between immediate cash inflows and foregone future roya

IntelGenx Corp. pitch deck: common questions

What does IntelGenx Corp. do, according to its 2016 investor presentation?

IntelGenx is a publicly listed specialty pharmaceutical company that develops **oral thin film (VersaFilm™)** and tablet-based drug delivery technologies to make existing approved drugs easier to take and potentially faster-acting, targeting large markets such as migraine, opioid dependence, erectile dysfunction, and schizophrenia.

What are the main themes of IntelGenx’s February 18, 2016 investor presentation?

The February 18, 2016 deck focuses on IntelGenx’s **VersaFilm™ oral thin film platform**, its drug pipeline (including Rizaport™ oral film for migraine), record Q3 2015 financial results, and the build-out of in-house manufacturing capabilities to support commercialization of multiple thin-film products.

Which products and indications does the IntelGenx 2016 deck emphasize?

At the time of the 2016 deck, IntelGenx highlighted **Forfivo XL® tablets** (an extended-release antidepressant) and its oral thin film **Rizaport™** for migraine as key commercial and late-stage assets, along with target thin-film formulations for Suboxone (opioid dependence), Cialis® (erectile dysfunction), and certain antipsychotics for schizophrenia.

Was the 2016 investor presentation tied to a specific fundraising transaction?

While the 2016 deck itself is an investor overview rather than a disclosed private round, IntelGenx subsequently executed public-market financings: notably, in August 2016 it sold its U.S. royalty on future Forfivo XL® sales to SWK Holdings for **$6 million (approximately CAD$8 million)**, calling it the largest capital influx in the company’s history, and in July 2017 it completed a **CDN$6.838 million convertible debenture offering** to fund capital expansion, clinical studies, product development, and working capital.

What is Rizaport™, and what progress had IntelGenx made with it around 2016?

Rizaport™ is IntelGenx’s **proprietary oral thin film formulation of rizatriptan** for the treatment of migraine, developed using its VersaFilm™ technology; by 2016 the company had obtained its **first European marketing approval** for Rizaport™, and it later announced patent grants protecting the film formulation in the U.S. and Europe.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

IntelGenx Corp. pitch deck slides

IntelGenx Corp. pitch deck slide 1 of 17 — IntelGenx Corp. pitch deck — slide 1 of 17

IntelGenx Corp. pitch deck slide 2 of 17 — IntelGenx Corp. pitch deck — slide 2 of 17

IntelGenx Corp. pitch deck slide 3 of 17 — IntelGenx Corp. pitch deck — slide 3 of 17

IntelGenx Corp. pitch deck slide 4 of 17 — IntelGenx Corp. pitch deck — slide 4 of 17

IntelGenx Corp. pitch deck slide 5 of 17 — IntelGenx Corp. pitch deck — slide 5 of 17

IntelGenx Corp. pitch deck slide 6 of 17 — IntelGenx Corp. pitch deck — slide 6 of 17

What each slide of the IntelGenx Corp. pitch deck says

Slide 1

IntelGen y Corp. Innovative Drug Delivery Solutions We Make Approved Drugs Better February 18, 2016 TSX-V: IGX OTCQX: IGXT

Slide 2

Forward Looking Statements To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar express…

Slide 3

IntelGen y Corp. Oral Thin Films Provide Significant Market Opportunities for Improving Drug Delivery IGX CEO co-developer of the Listerine breath strips Oral films ideal for elderly, children, patients who have difficulty swallowing traditional tablets Quicker action to relieve symptoms

Slide 4

Making Approved Drugs Better Through Innovative Drug Delivery Solutions IntelGenx develops and manufactures faster and more efficient drug delivery systems for top pharmaceuticals IntelGenx Drug Delivery Technology Platforms Films Tablets Controlled-release tablets for oral Rapidly disintegrating film improving ) ) ) absorption over an extended time period drug performance and easing administration without the need for water VersaFilm™ VersaTab™ AdVersa™ Rizaport™ IntelGen y Corp.

Slide 5

Investment Highlights - Developing proprietary oral drug delivery technologies to address $19B TAM - Market momentum with Forfivo XL @ tablets - Achieved first European marketing approval of RIZAPORT™ for Migraines - Robust product pipeline to enable expansion into other market segments with significant TAM - Achieved record Q3 revenue and profitability IntelGeny Corp. VersaFilm™ $17B TAM VersaTab™ $1.7B TAM

Slide 6

FORFIVO XL® — First 450mg tablet approved by = FDA for major depressive disorder + High dose version of Wellbutrin XL® FORFIVO XL® NET SALES ($Thousands) - Only approved, once-daily, bupropion FE HCI 450mg dose in a single tablet $2,500 + Launched commercially October 2013 in $2,132 partnership with Edgemont oor $1756 peat Pharmaceuticals ’ $1,697 iia + Q3 2015 net sales grew 16% compared to $1,195 a Q2 2015, with net sales at $2.5 million A ($4.7 million gross) - vert? - For the past nine months, net sales totaled $6.3 million ($12 million gross), an increase of 117% compared to the nine month period in 2014 5 3014 4Q14 1Q15 2015 3015 IntelGen y Corp.

Slide 7

VersaFilm™ Oral Thin Films Drug Delivery Technology Over $17B Market Opportunity and Growth Platform for IGX Benefits of VersaFilm™ - Improves patients compliance who have OPIOD DEPENDENCE MIGRAINE problems swallowing tablets and capsules to Targeted Suboxone Targeted Rizatriptan more easily take medication Sales Market - Rapid disintegration without the need for water $1 .7B $2B - Improves absorption — faster onset of action « Potential for reduced adverse effects ERECTILE SCHIZOPHRENIA ; DYSFUNCTION $17B Addressable Market Target(;daltt;xaplne Targeted Cialis® - Successful pivotal bioequivalence studies $ 52B Sales + Two film products awaiting FDA approval ) $4-ZB « Limited number of comp…

Slide 11

In-House Manufacturing Approach Full Manufacturing Capabilities Establishing manufacturing capability to increase profitability v Integrate pharmaceutical services and IP protection v Reduce dependence by IntelGenx on external manufacturing partners v Offer clients the advantage to obtain all services from one source ("one-stop shopping") v Increase R&D capabilities with expanded laboratories and technologies IntelGen y Corp. Blending Coating Packaging

Slide text above is read directly from the IntelGenx Corp. deck PDF embedded on this page.